Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reaction
Fetal abnormalities linked to sartan use in last 6 months of pregnancy
May 12th, 2005
Like angiotensin-converting enzyme (ACE) inhibitors, AT1 receptor antagonist use by women in the last 6 months of pregnancy has been linked to development of fetal abnormalities. According to a study from Canada, "Angiotensin II (A-II) is the main effector of the renin-angiotensin system. A-II functions by binding its type 1 (AT1) receptors to cause vasoconstriction and retention of sodium and fluid. Several AT1 receptor antagonists - a group of drugs collectively called sartans - have been marketed during the past few years for treatment of hypertension and heart failure. "At least 15 case reports describe oligohydramnios, fetal growth retardation,...
Source: Women's Health Weekly (2005-05-12)
|
